title: What Is the best treatment for HIV-associated multicentric Castleman disease?
authors.affiliation: Department of Oncology, Chelsea & Westminster Hospital, London, United Kingdom. m.bower@imperial.ac.uk
authors.forename: Mark
authors.initials: M
authors.lastname: Bower
authors.forename: Alessia
authors.initials: A
authors.lastname: Dalla Pria
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D005871:Castleman Disease / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy*; D015658:HIV Infections / Q000150:complications; D006801:Humans; D000069283:Rituximab
chemical_list: D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; D000069283:Rituximab